Glibenclamide Solicitud
1.Hypoglycemic drugs,for the treatment of mild,non insulin dependent diabetes mellitus
2.Glibenclamide and glibenclamide,glibenclamide,which belongs to the second generation oral sulfonylurea drugs,with the mechanism of toluene sulfonyl Ding Niao,its hypoglycemic effect was the strongest sulfonylurea,intensity for tolbutamide 200~250 times.Be selective effect on pancreatic beta cells,promote the secretion of insulin,can enhance the hypoglycemic effect of exogenous insulin,insulin receptor after strengthening effect.
3.Glibenclamide is one of the drugs currently used to treat type 2 diabetes,the most often used,because the utility function is fast and strong,so after the application has obvious effect,can effectively control blood sugar,high blood sugar,is applicable to other sulfonylurea hypoglycemic effect not beautiful person.
|
product Name: |
5-Chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]-aminado]sulfonyl]fenilo]-ethyl]-2-methoxybenzamide |
| Sinónimos: |
LABOTEST-BB LT00244861;GLYBENCLAMIDE;GLYBENZCYCLAMIDE;GLYBURIDE;GIBENCLAMIDE;
GLIBENCLAMIDE;5-CHLORO-N-[4-(CYCLOHEXYLUREIDOSULFONYL)FENETILO]-2-METHOXYBENZAMIDE;5-CHLORO-N-[2-[4-[[[(CYCLOHEXYLAMINO)CARBONYL]AMINO]-SULFONYL]PHENYL]ETHYL]-2-METHOXYBENZAMIDE |
| CASO: |
10238-21-8 |
| MF: |
C23H28ClN3O5S |
| MW: |
494 |
| EINECS: |
233-570-6 |
| Categorías de Producto: |
Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts;Organics;Amino Acids &
Derivatis;Isotope Labeled Compounds;API’s;Potassium channel;Ion Channels;Isotope Labelled Compounds;API;GLYNASE;Diabetes Research |
| Archivo Mol: |
10238-21-8.mol |
Gerente de ventas